{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-1EH69OLL/c7f009b0-d307-47cb-b466-c9714763a695/PDF","dcterms:extent":"1178 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-1EH69OLL/a850c328-3fc6-4a43-a519-c41f49337c86/TEXT","dcterms:extent":"24 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-1EH69OLL","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2020","dc:creator":["Anderluh, Marko","Jakopin, Žiga","Tomašič, Tihomir"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:71"},{"@xml:lang":"sl","#text":"str. 133-140"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:21003267","URN:URN:NBN:SI:doc-1EH69OLL"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"covid-19"},{"@xml:lang":"sl","#text":"koronavirus"},{"@xml:lang":"sl","#text":"Pandemije"},{"@xml:lang":"sl","#text":"protivirusne učinkovine"},{"@xml:lang":"sl","#text":"SARS-CoV-2"},{"@xml:lang":"sl","#text":"Virusne infekcije"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Protivirusne učinkovine proti SARS-CoV-2 za zdravljenje bolezni covid-19| Antiviral drugs against SARS-CoV-2 for the treatment of covid-19|"},"dc:description":[{"@xml:lang":"sl","#text":"The covid-19 disease, which is caused by SARSCoV-2, can be fatal. Therefore, there is an urgent need for the development of novel antiviral drugs against SARS-CoV-2. In this review article, we describe macromolecular structures of SARS-CoV-2 as potential targets for antiviral drugs. Furthermore, we present drugs or drug candidates with antiviral mode of action and promising effects in covid-19 therapy"},{"@xml:lang":"sl","#text":"Bolezen covid-19, ki jo povzroča novi koronavirus, je lahko tudi smrtna, zato je razvoj novih protivirusnih učinkovin z delovanjem proti SARS-CoV-2 izrednega pomena. V preglednem članku bomo predstavili makromolekulska prijemališča virusa SARSCoV-2 kot potencialne tarče za razvoj zdravilnih učinkovin ter učinkovine ali kandidate za učinkovine, ki delujejo protivirusno in kažejo obetavne učinke v terapiji covid-19"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-1EH69OLL","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-1EH69OLL"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-1EH69OLL/c7f009b0-d307-47cb-b466-c9714763a695/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-1EH69OLL/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-1EH69OLL"}}}}